European Multicenter Study on Role of Lymph Node Dissection in Surgical Management of Adrenal Cortical Carcinoma (LACC)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Adrenocortical carcinoma (ACC) is a rare malignancy with an estimated annual incidence of only 0.5 to 2.0 per million population and a high rate of mortality: Stage I, II and III 5 years-survival is respectively 84%, 63% and 24%, while medium survival is less than 12 months for metastatic disease. Stage of the disease, age at diagnosis, tumour grading and complete surgical resection are the main prognostic factors. Surgical treatment is the only effective therapeutic strategy for ACC and recent guidelines recommend loco-regional lymph node dissection as a fundamental surgical element in order to guarantee complete resection. However, adrenal lymphatic drainage can be variable. The main collecting lymph nodes representing the first tiers in the lymphatic drainage are the peri-adrenal nodes and the renal ilum nodes. In addition, the posterior lymphatic drainage flows to lymph nodes located posterior to the IVC, and on the right edge of the aorta for the right adrenal gland, or on its right left edge for the left gland, stretching from the celiac region near the diaphragmatic crus to the renal vessels.
The anterior lymphatic drainage flows downward to the lumboaortic nodes and ends in the interaortocaval space, on the right edge of the aorta for the right adrenal gland, and on its right left edge for the left gland and mainly around the renal hilum. Collecting nodes can be located below the renal pedicle, sometimes extending as far as the origin of the iliac vessel. Most authors concur in describing a lymphatic drainage that passes through the diaphragm directly into the posterior mediastinal nodes. A majority of lymphatic channels run medially to the thoracic duct, often without the involvement of any lymph nodes. Furthermore, it is impossible to predict which pathway would be involved in case of a malignant lesion, because all pathways would probably be involved simultaneously because of the size, often >10 cm, of ACC at diagnosis, and considering that the lymphatic stream can be disorganized because of the tumour volume or lymph node involvement. Therefore, the extent of lymph node dissection in order to involve other stations should be considered only on the basis of pre-operative radiological evidence and intra-operative evaluation. Despite aggressive surgical resection, local and distant recurrence rate after R0 surgery remains as high as 50-80%, potentially because of the lack of an accurate identification of the nodes stations for the lymph node dissection. Indeed, nodes drain disorganization due to the high tumour volume makes impossible to predict accurately the lymphatic metastatic pathway. In this context, the rarity of ACC leads to heterogeneity of the scientific studies and consequently to the lack of perspective works, so that tumour recurrence evaluation refers to patients categories who underwent lymph node dissection with or without preoperative evidence of nodal disease
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Francesco Pennestrì, Dr
- Phone Number: +393280244528
- Email: francesco.pennestri@policlinicogemelli.it
Study Locations
-
-
-
Rome, Italy, 00168
- Recruiting
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
-
Contact:
- Francesco Pennestrì, Dr
- Phone Number: +393280244528
- Email: francesco.pennestri@policlinicogemelli.it
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria: All adult (18 years old and older) patients that underwent surgery with a final histology of adrenocortical carcinoma from 2015 till 2021
Inclusion Criteria:
- All adult (18 years old and older) patients
- underwent surgery
- final histology of adrenocortical carcinoma
- among European centers that participate in the Eurocrine® database between 2015 and 2021
Exclusion Criteria:
- Patients <18 years old
- Patients with metastatic disease at time of clinical referral
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Adrenalectomy in patients operated for Adrenocortical Carcinoma
All adult (18 years old and older) patients registered in EUROCRINE® database that underwent surgery for adrenocortical carcinoma from 2015 till 2021 will be included
|
Regarding lymphadenectomy extent, it will be described as locoregional or systematic depending on availability of data in the Eurocrine database.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Adrenocortical Carcinoma (ACC) among European endocrine centers
Time Frame: January 2015- January 2021
|
Identification of the number of patients who underwent adrenalectomy for diagnosis of ACC among European centers participating in the Eurocrine database
|
January 2015- January 2021
|
|
Extent of lymphadenectomy
Time Frame: January 2015- January 2021
|
Evaluation of the lymph node dissection extension (in terms of number of lymph nodes and nodal stations dissected during surgical treatment for ACC)
|
January 2015- January 2021
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Oncologic outcomes
Time Frame: January 2015- January 2021
|
Descriptive analysis of oncologic outcome (in terms of disease recurrence, lymph node metastasis and their association to the tumour stage) in patients who underwent surgical treatment of ACC in European centers
|
January 2015- January 2021
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Marco Raffaelli, Prof, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 5171
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adrenocortical Carcinoma
-
NCT06487481RecruitingCarcinoma, Adrenal Cortical | Carcinoma, Adrenocortical | Adrenocortical Carcinoma (ACC) | Recurrent Adrenocortical Carcinoma (ACC) | Recurrent Abdominal Adrenocortical Carcinoma (ACC)
-
NCT00848016CompletedRecurrent Adrenocortical Carcinoma | Stage III Adrenocortical Carcinoma | Stage IV Adrenocortical Carcinoma
-
NCT00778817TerminatedRecurrent Adrenocortical Carcinoma | Stage III Adrenocortical Carcinoma | Stage IV Adrenocortical Carcinoma
-
NCT07141147Not yet recruitingRadiotherapy | High-risk Localized Adrenocortical Carcinoma
-
NCT07189403RecruitingMetastatic Castration-resistant Prostate Cancer | Advanced or Metastatic Adrenocortical Carcinoma
-
NCT06279442RecruitingCarcinoma Adrenal | Carcinoma, Adrenocortical Recurrent
-
NCT00215202CompletedNonresectable Adrenocortical Carcinoma
-
NCT07085572RecruitingAdrenal Cortical Carcinoma
-
NCT00003453TerminatedStage IV Adrenocortical Carcinoma
-
NCT00071058Completed
Clinical Trials on Adrenalectomy with or without lymphadenectomy
-
NCT05796960RecruitingThyroid Neoplasms | Thyroid Cancer, Papillary | Thyroid Cancer, Follicular | Thyroid Carcinoma | Thyroid Cancer | Anaplastic Thyroid Cancer | Thyroid Medullary Carcinoma
-
NCT07577427Not yet recruitingAdrenal Gland Disease
-
NCT04453943UnknownSpinal Cord Injuries | Paraplegia, Spinal | Paraplegia, Incomplete
-
NCT05592639Active, not recruitingMelanoma | Penile Cancer | Inguinal Lymphadenopathy
-
NCT02787187CompletedPancreatic Ductal Adenocarcinoma
-
NCT06019910RecruitingObesity | Dyslipidemias | Blood Pressure | Dysglycemia
-
NCT03666741Active, not recruitingAortic Valve Stenosis
-
NCT02364063CompletedDaytime Urinary Incontinence
-
NCT00980941CompletedDiabetes Prevention | Obesity Prevention